Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma

Patrizia Mondello(WinnMed), Michael R. Green(Harvard University), David A. Scheinberg(Memorial Sloan Kettering Cancer Center), Robert G. Roeder(Rockefeller University), Sreejoyee Ghosh(The University of Texas MD Anderson Cancer Center), Ari Melnick(Cornell University), Man Chun John(The University of Texas MD Anderson Cancer Center), Neeraj Jain(The University of Texas MD Anderson Cancer Center), Ahmet Doǧan(Memorial Sloan Kettering Cancer Center), Haopeng Yang(Peking University), Cassian Yee(The University of Texas MD Anderson Cancer Center), Matt Teater(Cornell University), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Hsia‐Yuan Ying(Cornell University), Chi-Shuen Chu(Genomics Research Center, Academia Sinica), Oliver Weigert(German Cancer Research Center), Shailbala Singh(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Anas Younes(Intercept Pharmaceuticals (United States)), Stefan Alig(Heidelberg University), Aaron Y. Chang(Memorial Sloan Kettering Cancer Center), Lorena Fontán(Cornell University), Eneda Toska(Johns Hopkins University), Anja Mottok(Comprehensive Cancer Center Mainfranken), Matthew Durant(Cornell University), Saber Tadros(University of Nebraska Medical Center), Elisa de Stanchina(Memorial Sloan Kettering Cancer Center), José Baselga(Harvard University), Giorgio Inghirami(Cornell University)
Cancer Discovery
January 8, 2020
Cited by 159


Related Papers